PPARA and metabolic dysfunction-associated steatohepatitis: Saroglitazar, another dual PPARα/γ agonist that is approved in India for the treatment of diabetic dyslipidemia and MASH, has shown potential in reducing liver fat content, inflammation, and fibrosis in early trials, and further research is ongoing (34).